Showing items 1 - 4 of 4

Your selections:

Pharmacogenetics testing (DPYD and UGT1A1) for fluoropyrimidine and irinotecan in routine clinical care: Perspectives of medical oncologists and oncology pharmacists

- Glewis, Sarah, Lingaratnam, Senthil, Krishnasamy, Michael, Martin, Jennifer H., Tie, Jeanne, Alexander, Marliese, Michael, Michael

Pharmacogenetics of cyclophosphamide and CYP2C19 polymorphism in Thai systemic lupus erythematosus

- Ngamjanyaporn, Pintip, Thakkinstian, Ammarin, Verasertniyom, Oravan, Chatchaipun, Porntip, Vanichapuntu, Monchand, Nantiruj, Kanokrat, Totemchokchyakarn, Kitti, Attia, John, Janwityanujit, Suchela

The risk of coronary thrombosis with cyclo-oxygenase-2 inhibitors does not vary with polymorphisms in two regions of the cyclo-oxygenase-2 gene

- McGettigan, Patricia, Lincz, Lisa F., Henry, David, Attia, John, McElduff, Patrick, Bissett, Linda, Peel, Roseanne, Stokes, Barrie, Hancock, Stephen, Henderson, Kim, Seldon, Michael

Long-term efficacy of oral deferiprone in management of iron overload in beta thalassemia major

- Goel, Himanshu, Girisha, K. M., Phadke, Shubha

  • 1
  • Disclaimer
  • Privacy
  • Copyright
  • Contact
  • Deposit